Stock listing
Veru Inc.
Selected listing: A41ES4 · LSX · EUR · DE
Veru Inc. (LS Exchange: A41ES4), Health Technology. Latest release Sep 8, 2026: Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing…
- Ticker
- LS Exchange: A41ES4
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS Exchange
- Currency
- EUR
Latest news from Veru Inc.
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
September 8, 2026
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
September 2, 2026
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
August 10, 2026
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
August 4, 2026
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
August 3, 2026
Events
Research Veru Inc.
Alternate listings
VERU:NASDAQ
US · USD
Alternate listing for Veru Inc.; the primary context on this page is A41ES4:LSX.
VERU:BOATS
US · USD
Alternate listing for Veru Inc.; the primary context on this page is A41ES4:LSX.
FMW0:GETTEX
DE · EUR
Alternate listing for Veru Inc.; the primary context on this page is A41ES4:LSX.
FMW0:FWB
DE · EUR
Alternate listing for Veru Inc.; the primary context on this page is A41ES4:LSX.
A41ES4:LS
DE · EUR
Alternate listing for Veru Inc.; the primary context on this page is A41ES4:LSX.
FMW0:MUN
DE · EUR
Alternate listing for Veru Inc.; the primary context on this page is A41ES4:LSX.